0001733413 false 0001733413 2021-11-04 2021-11-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 4, 2021

 

 

 

TFF PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39102   82-4344737
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification Number)

 

3801 S. Capital of Texas Hwy, Suite 330

Austin, Texas 79704

(Address of principal executive offices)

 

(737) 802-1973

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Securities registered pursuant to Section 12(b)of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock: Par value $.001   TFFP   Nasdaq Global Market

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On November 4, 2021, TFF Pharmaceuticals, Inc. held its 2021 Annual Meeting of Stockholders, for the purposes of:

 

Electing eight directors, each to serve until our 2022 Annual Meeting of Stockholders;

 

Authorizing and approving our 2021 Stock Incentive Plan; and

 

Ratifying the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.

 

All of the persons nominated to serve on our board of directors, namely Aaron Fletcher, Glenn Mattes, Brian Windsor, Robert S. Mills, Stephen C. Rocamboli, Harlan Weisman, Randy Thurman, and Malcolm Fairbairn, were elected to our board of directors, with shares voted as follows:

 

Name  For   Withheld  

Broker

Non-Vote

 
Aaron Fletcher   10,505,299    660,260    6,568,344 
Glenn Mattes   10,560,825    604,734    6,568,344 
Brian Windsor   10,755,152    410,407    6,568,344 
Robert S. Mills   10,160,672    1,004,887    6,568,344 
Stephen C. Rocamboli   10,735,650    429,909    6,568,344 
Harlan Weisman   10,434,881    730,678    6,568,344 
Randy Thurman   10,756,709    408,850    6,568,344 
Malcolm Fairbairn   10,759,700    405,859    6,568,344 

 

Further, our shareholders authorized and approved, and therefore adopting, our 2021 Stock Incentive Plan, with shares voted as follows:

 

For   8,243,575 
Against   2,334,031 
Abstain   587,953 
Broker Non-Vote   6,568,344 

 

In addition, our shareholders ratified the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021, with shares voted as follows:

 

For   17,648,123 
Against   17,237 
Abstain   68,543 

 

There were no broker non-votes on the ratification of our independent registered public accounting firm.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TFF PHARMACEUTICALS, INC.

 

Dated: November 10, 2021 /s/  Kirk Coleman
  Kirk Coleman,
  Chief Financial Officer

 

 

2